DivestmentJul 30, 2026, 04:41 PM
Waldencast Completes Sale of Obagi Medical for up to $460M
AI Summary
Waldencast plc announced the completion of the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint. The transaction is valued at up to $460 million, marking a significant step in Waldencast's strategy to strengthen its balance sheet and accelerate the global growth of Milk Makeup. In conjunction with the closing, Waldencast repaid its outstanding senior term loan facility, and key executives, including the founders and CFO, transitioned to lead Obagi Medical, with Felipe Dutra assuming the role of principal executive and financial officer for Waldencast.
Key Highlights
- Waldencast completed the sale of its Obagi Medical business to Bridgepoint.
- The transaction is valued at up to $460 million, subject to adjustments.
- The sale strengthens Waldencast's balance sheet and allows focus on Milk Makeup.
- Company repaid all outstanding senior term loan facility.
- Waldencast founders Michel Brousset, Hind Sebti, and CFO Manuel Manfredi transitioned to Obagi Medical.
- Felipe Dutra, Executive Chairman, will serve as principal executive and financial officer.
Price Impact
More from WALD